comprehensive -WSS

comprehensive

author：focus 2025-09-14 14:49:20 - browse：53

Joaquin Duato -- health policy coverage from STAT — Johnson & Johnson CEO Joaquin Duato MICHAEL BUHOLZER/AFP via Getty Images

WASHINGTON — Merck CEO Robert Davis and Johnson & Johnson CEO Joaquin Duato have agreed to voluntarily testify before the Senate health committee, avoiding a threatened subpoena, the committee announced Friday.

The decision by the executives came after a public pressure campaign by Sanders to get the two executives and Bristol Myers Squibb CEO Chris Boerner to testify about why prices for their drugs are higher in the United States than in other countries. Sanders had scheduled a vote to subpoena the Merck and Johnson & Johnson CEOs on Jan. 31, but canceled it on Friday.

“The use of a subpoena was clearly a last resort and I’m delighted that these CEOs will be coming into our committee voluntarily,” Sanders said in a written statement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： The Harvard botanist who searched for psychedelics in the Amazon

focus

WSS

Medicare inequities exacerbate Puerto Rico’s health disparities

Think you might have Covid

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Parkinson’s finding may lead to tests and, someday, treatments

Alabama frozen embryo ruling has major implications for IVF clinics

NIH study of ME/CFS points to clear biological hallmarks

entertainment

comprehensive

knowledge

After affirmative action ruling, medical educators look to 'holistic review'

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Trump demands the U.S. pay no more for drugs than other countries … again

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Alkermes shareholders re

Alabama IVF ruling threatens families facing fatal genetic disease

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

New documents shed light on MD Anderson Cancer Institute feud

In Memoriam: Notable people who died in 2023

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

hotspot

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

STAT readers on older presidents, polypills, Medicare, and more

A new nitrogen execution bill also undermines medical licensing

The Harvard botanist who searched for psychedelics in the Amazon

AI generated plenty of interest at JPM but not a lot of trust

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

entertainment

focus

hotspot

focus